Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Promacta Gets ODAC Nod Despite Concerns Of Off-Label, Long-Term Use

Executive Summary

Despite concerns over off-label use of GlaxoSmithKline's Promacta, FDA's Oncologic Drugs Advisory Committee unanimously backed the drug for short-term use, voting 16-0 that the clinical data demonstrate a favorable risk-benefit ratio

You may also be interested in...



Amgen’s Nplate Has First Mandatory Patient Registration Under REMS

The Risk Evaluation and Mitigation Strategy for Amgen's platelet producer Nplate mandates enrollment at three levels of a controlled distribution system: institutions, physicians and patients

Amgen’s Nplate Has First Mandatory Patient Registration Under REMS

The Risk Evaluation and Mitigation Strategy for Amgen's platelet producer Nplate mandates enrollment at three levels of a controlled distribution system: institutions, physicians and patients

With Promise Of Post-Market Safety Studies, Panel Backs Amgen’s Nplate

FDA's new authority to require post-market studies under the FDA Amendments Act could be the ticket to approval for Amgen's platelet producer Nplate (romiplostim)

Related Content

UsernamePublicRestriction

Register

PS049700

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel